Precision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B Transcript
Precision BioSciences prices 10.24M shares at $7.75 in underwritten offering
Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
UPDATE: Precision BioSciences Q3 Adj. EPS $(0.74) Beats $(0.85) Estimate
Precision BioSciences: Q3 Earnings Snapshot
Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences Q3 EPS $(0.28) Beats $(0.85) Estimate
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences Doses First Patient In The Phase 1/2 Function-DMD Clinical Trial Evaluating PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy
iECURE Announces Updated Safety And Metabolic Control Data From Phase 1/2 Trial Of ECUR-506 In Neonatal-Onset OTC Deficiency To Be Presented August 27 At SSIEM Symposium
Precision BioSciences: Promising HBV Editing Evidence
Precision BioSciences (NASDAQ:DTIL) Passes Minervini Trend Template and High-Growth Momentum Screen
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.